Quarterly profit jumped 179% to $14.2 million at Vericel
Vericel Corporation reported Q3 2026 net income rose 179% to $14.2M, with total revenue up 26% to $85.4M. MACI and Burn Care segments drove growth, with gross margin at 73%. The company raised full-year revenue guidance to $344M-$346M and adjusted EBITDA margin to 28%. Vericel repurchased $8.8M in shares and has $191.2M remaining in authorization.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance raise indicate strong demand and cash generation, supporting a bullish outlook.
Market read
First‑report earnings and guidance raise for a small‑cap biotech, offering a clear trading catalyst.
What to watch
Potential regulatory or reimbursement risks for MACI and burn‑care products.
Background
Vericel is a niche biotech focused on sports‑medicine and burn‑care cell therapies.
Ticker impact
Vericel reported Q3 2026 earnings with net income up 179% to $14.2M and raised full-year revenue guidance to $344‑$346M.
likely upside as market prices in higher revenue and profit guidance
Revenue and profit beat expectations and guidance was increased, which typically drives the stock higher in the short term.
Market effects
Boosts sentiment for biotech/medical‑device sector as a peer shows strong growth.
Positive for US small‑cap biotech listings.
Limited to niche advanced‑therapy market.
Counterpoint
If guidance is overly optimistic, the stock could face disappointment on later quarters.
Key entities
- companyVericel Corporation
NASDAQ‑listed biotech delivering advanced cell therapies.
